Abstract:Purpose: Gene therapy combined with radiation has shown promising potential for the treatment of tumors. This paper aimed to clarify the synergistic effect of radiotherapy combined with the bladder cancer tissue-specific oncolytic adenovirus (Ad-PSCAE-UPII-E1A) on bladder cancer cells and to study the underlying synergy mechanisms of the combined treatment. Materials and methods: The Adenovirus carrying E1A under control of UPII promoter and prostate stem cell antigen enhancer (PSCAE) were successfully constructed. The viability of bladder cancer cells BIU-87 and EJ was determined by MU assay. The apoptotic assay was demonstrated by flow cytometry and TEM. Virus titer was determined by TCID50 assay, and proteins Mre11, Chk2-Thr68, and El A were analyzed by Western blot method. Results: Oncolytic adenovirus combined with radiotherapy improved antitumor efficacy compared with the single treatment at a time and was X-ray dosage-dependent. When the adenovirus infection was scheduled at 24h after irradiation, cancer cells had the lowest viability. Adenovirus and irradiation induced cell death through the caspase-3 related apoptotic pathway, and bladder cancer cells were arrested at the G1 (BIU-87) or S phase (EJ). Autophagic vacuoles were observed in bladder cancer cells treated with radiation and adenovirus. After irradiation, more virus particles were observed in the BIU87 and EJ cells. However, by a TCID50 assay, there was no difference in virus titter between irradiated bladder cancer cells and unirradiated cells. The proteins Mre11, Chk2-Thr68 which involved in the DNA break repair pathway were decreased while gamma-H2AX-Ser139 increased; at the same time, the E1A gene and the hexon proteins of oncolytic adenovirus were increased after irradiation. Conclusions: Our results proved synergistic antitumor effect of adenovirus Ad-PSCAE-UPII-E1A and radiation, which might be a potential therapeutic strategy for bladder cancer.

Feasibility of Oncolytic Adenovirus Labeled With Radionuclides for Treating Tumors

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

[Advances in research on oncolytic adenoviruses in tumor therapy]

Menstrual Blood-Derived Stem Cells As Delivery Vehicles for Oncolytic Adenovirus Virotherapy for Colorectal Cancer

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Radiofrequency Hyperthermia Enhances Locally Delivered Oncolytic Immuno-Virotherapy for Pancreatic Adenocarcinoma

Impact of Oncolytic Viruses in Combination with Radiotherapy on Tumor Cells

Feasibility of Herpes Simplex Virus Type 1 Mutants Labeled with Radionuclides for Tumor Treatment

Progress of Target Therapy with Oncolytic Adenovirus for Cancer

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy

Imaging of radioiodine-labeled KH901, a tumor-specific oncolytic recombinant adenovirus, in nude mice with human hepatocellular carcinoma.

Delivery of Oncolytic Adenovirus into the Nucleus of Tumorigenic Cells by Tumor Microparticles for Virotherapy

Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy

A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.

Antitumor and Radiosensitization Effect of 12 C 6+ Heavy-Ion Irradiation Mediated by Radiation-Inducible Gene Therapy

Oncolytic (replication-competent) adenoviruses as anticancer agents

Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy

Effect of Combined Treatment of Radiation and Tissue-Specific Recombinant Oncolytic Adenovirus on Bladder Cancer Cells

Application of Conditionally Replicating Adenoviruses in Tumor Early Diagnosis Technology, Gene-Radiation Therapy and Chemotherapy

Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations

Potentiation of Tumor Radiotherapy by A Radiation-Inducible Oncolytic and Oncoapoptotic Adenovirus in Cervical Cancer Xenografts